May 18, 2022 7:30 am EDT Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)
Mar 2, 2022 7:30 am EST Avalo Therapeutics Reports 2021 Financial Results and Provides Business Updates
Jan 6, 2022 7:30 am EST Avalo Reports Positive Phase 1b Results for AVTX-002 in Moderate to Severe Crohn's Disease Patients and Presents Additional Program Updates at 2022 Investor Event
